Introduction
============

*Mycobacterium tuberculosis* is the causative agent of tuberculosis (TB) in humans and presumably infects a third of the world's population.[@b1-idr-11-1237] According to the latest information of TB epidemic provided by the World Health Organization Global Tuberculosis Report 2017, TB causes ill-health in \~10 million people each year and is one of the top 10 causes of death worldwide. For the past 5 years, it has been the leading cause of death from a single infectious agent, ranking above HIV/AID. The innate immune response induces activation of the T helper 1-type immune system and plays an important role in host defense against the pathogenesis of TB.[@b2-idr-11-1237] Unraveling genetic factors contributing to TB risk may lead to improved treatment and prevention of this disease.[@b3-idr-11-1237],[@b4-idr-11-1237]

Mannose-binding lectin (MBL) is a calcium-dependent plasma collagenous lectin which plays an important role in innate immune defense against infectious agents.[@b5-idr-11-1237] MBL is synthesized in liver and circulates as oligomers complexed with MBL-associated serine proteases (MASPs)[@b6-idr-11-1237] and the lectin pathway of the complement system, generating non-specific immune responses.[@b7-idr-11-1237],[@b8-idr-11-1237] MASPs are activated to initiate the lectin pathway of complement activation, which results in opsonization and phagocytosis or lysis of microorganisms. Besides its direct action as an opsonin and its key role in the lectin pathway, MBL may modulate inflammatory responses and immune activation.[@b6-idr-11-1237]

MBL production is encoded by the *MBL2* gene that lies in chromosome 10, and polymorphisms of the structural regions of the gene or its promoter have been associated with relative or absolute serum MBL deficiencies. The presence of three mutations in exon 1 of the *MBL2* gene which are known for their functional effect at codons 52(rs5030737), 54(rs1800450), and 57(rs1800451). The three variants can impede the assembly of MBL subunits into the basic trimer structure and make the subunits more vulnerable to degradation, thereby reducing the amount of functional MBL subunits in heterozygous individuals.[@b9-idr-11-1237] The variant mutant alleles are allele B of codon 54, allele C of codon 57, and allele D of codon 52 in exon 1. The normal wild-type allele is commonly designated as A, and the three variant alleles are designated as O.[@b9-idr-11-1237]--[@b11-idr-11-1237] A number of genetic studies have been performed to consider the impact of MBL2 polymorphisms on the development of TB disease, leading to conflicting results. A previous meta-analysis suggested that MBL2 polymorphisms were not significantly associated with susceptibility to pulmonary TB infection,[@b12-idr-11-1237] while another meta-analysis demonstrated that MBL2 exon 1 polymorphisms (rs1800451 and rs1800451) played a protective role against the development of TB disease. Recently several new case--control studies have been published, some of which reported controversial results compared with previous publications.

In this study, we comprehensively collected and pooled all eligible articles using meta-analysis with the aim to better clarify the association between currently reported MBL2 exon 1 polymorphisms and TB susceptibility.

Materials and methods
=====================

Search strategy
---------------

This meta-analysis was conducted and reported in accordance with the PRISMA guidelines. We performed a systematic search of relevant literature using the databases PubMed, EMBASE, Chinese National Knowledge Infrastructure, and Chinese Biomedical database up to February 2, 2018 without time period and sample size limitations. The combination of search items included MeSH items and keywords of "mannose-binding lectin 2" or "MBL2"; ''rs1800450" or "rs1800451" or "rs5030737" or "polymorphism(s), single nucleotide" or ''variant'' or "variation" or ''allele'' or ''SNP''; "tuberculosis" (Supplementary material). Moreover, reference lists of related review articles, original studies, and conference abstracts were manually screened to identify additional articles that were not identified in the initial literature search described above.

Inclusion and exclusion criteria
--------------------------------

Studies were selected according to the following inclusion criteria: 1) case--control studies; 2) investigation on the association of MBL2 exon 1 polymorphisms (rs1800450, rs1800451, and rs5030737) with TB risk; 3) genotype distribution information in cases and controls. The major reasons for exclusion of studies were 1) repeated literature; 2) case-only studies and review articles; 3) studies without detailed genotype frequencies; 4) genotype frequencies found in the control group deviate from Hardy--Weinberg equilibrium (HWE).

Data extraction
---------------

Data of eligible studies were independently extracted by two authors (Wu and Yang) according to the above-mentioned selection criteria. The two authors reached a consensus on each item. The following data were collected: name of the first author, publication year, country where the study was conducted, ethnicity, source of controls, genotyping method, TB types, genotype frequency in cases and controls, and HIV status. Different ethnicities were categorized as Asian, Caucasian, and African. TB types were classified as pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB). All eligible studies were classified as hospital-based (HB), population-based (PB), and household/neighboring/working contacts--based (H/N/WB) according to the source of controls. The HWE in control population was judged by chi-square test. *P*-value \<0.05 was considered as a state of significant disequilibrium.

Statistical analysis
--------------------

Crude odds ratio (OR) with 95% confidence intervals (CIs) were calculated to investigate the strength of the association between MBL2 exon 1 polymorphisms (rs1800450, rs1800451, and rs5030737) and TB risk. The 95% CIs were used for statistical significance test and a 95% CI without 1.00 suggested significant difference. Pooled ORs were obtained from combination of single studies by five models: allele model (O vs A), homozygote comparison (OO vs AA), heterozygote comparison (AO vs AA), dominant model (AO/OO vs AA), and recessive model (OO vs AO/AA). Chi-square-based Q-test was applied to test the heterogeneity assumption, and the *P*-value of \<0.1 was considered to detect notable heterogeneity.[@b13-idr-11-1237] When Q-test showed the existence of notable heterogeneity, we used the random-effects model (DerSimonian and Laird method);[@b14-idr-11-1237] otherwise, the fixed-effects model (Mantel and Haenszel method) was applied for the pooling of the data.[@b15-idr-11-1237] *I*^2^ statistics was used to measure inter-study variability, and greater values indicated higher degree of heterogeneity.[@b13-idr-11-1237] Sensitivity analysis was conducted by removing one data set at a time to reflect the influence of the individual data set to the pooled ORs and assess the stability of the results. Stratification and logistic meta-regression analyses were performed to explore the source of heterogeneity by ethnicity, source of controls, genotyping method, and sample size (studies with \>800 participants were defined as "large," and studies with \<800 participants were defined as "small"). Publication bias was assessed using Begg's funnel plots[@b16-idr-11-1237] and Egger's regression method,[@b17-idr-11-1237] statistical significance was defined as *P*-value \<0.05. All *P*-values are two-sided. Statistical analysis was undertaken using STATA software (version 12.1; Stata Corp, College Station, TX, USA).

Results
=======

Study selection and characteristics of studies
----------------------------------------------

Previous studies have provided conflicting results about MBL2 exon 1 polymorphisms and TB risk; hence, it is necessary to clarify this association by a comprehensive meta-analysis. [Figure 1](#f1-idr-11-1237){ref-type="fig"} illustrates the study selection process. A total of 26 case--control studies,[@b18-idr-11-1237]--[@b43-idr-11-1237] including 7952 cases and 9328 controls, were identified according to inclusion and exclusion criteria. The time span of eligible studies was from January 1, 1998 to May 4, 2017. Among the 26 eligible studies, 14 were studies of Asians, nine studies were of Caucasians, and three studies were of Africans. The detailed characteristics of the eligible studies included in this meta-analysis are shown in [Table 1](#t1-idr-11-1237){ref-type="table"}.

Meta-analysis results
---------------------

The association strengths between MBL2 exon 1 polymorphisms with TB risk are shown in [Table 2](#t2-idr-11-1237){ref-type="table"}. Overall, a statistically significant increased risk of TB susceptibility was observed in allele model (O vs A: OR =1.18, 95% CI =1.01--1.38, *P*~heterogeneity~\<0.0001, *I*^2^=85.8%, [Figure 2A](#f2-idr-11-1237){ref-type="fig"}), homozygote comparison (OO vs AA: OR =1.49, 95% CI: 1.02--2.18, *P*~heterogeneity~\<0.0001, *I*^2^=79.1%), and dominant model (AO/OO vs AA: OR =1.20, 95% CI: 1.01--1.43, *P*~heterogeneity~\<0.0001, *I*^2^=83.5%, [Figure 2B](#f2-idr-11-1237){ref-type="fig"}). Furthermore, we performed subgroup analyses to explore the effect of ethnicity, TB types, source of control, genotyping method, and sample size.

In subgroup analyses ([Table 2](#t2-idr-11-1237){ref-type="table"}), when data were stratified according to ethnicity, a significant increased TB risk was found in allele model (O vs A: OR =1.29, 95% CI =1.11--1.51, *P*~heterogeneity~\<0.0001, *I*^2^=66.0%, [Figure 2A](#f2-idr-11-1237){ref-type="fig"}), homozygote comparison (OO vs AA: OR =1.67, 95% CI: 1.09--2.55, *P*~heterogeneity~=0.008, *I*^2^=54.2%), heterozygote comparison (AO vs AA: OR =1.26, 95% CI: 1.05--1.50, *P*~heterogeneity~=0.001, *I*^2^=62.9%), dominant model (AO/OO vs AA: OR =1.31, 95% CI: 1.10--1.56, *P*~heterogeneity~=0.001, *I*^2^=64.2%, [Figure 2B](#f2-idr-11-1237){ref-type="fig"}), and recessive model (OO vs AO/AA: OR =1.50, 95% CI: 1.01--2.22, *P*~heterogeneity~=0.023, *I*^2^=48.0%) for Asians. However, no significant association except a decreased trend was found in each model for Africans.

Likewise, when stratified by TB types, we found a significantly increased risk only in PTB among four models: allele model (O vs A: OR =1.23, 95% CI =1.04, 1.44, *P*~heterogeneity~\<0.0001, *I*^2^=85.7%), homozygote comparison (OO vs AA: OR =1.58, 95% CI: 1.05--2.36, *P*~heterogeneity~\<0.0001, *I*^2^=79.2%), heterozygote model (AO vs AA: OR =1.23, 95% CI: 1.04--1.45, *P*~heterogeneity~\<0.0001, *I*^2^=77.8%), and dominant model (AO/OO vs AA: OR =1.26, 95% CI: 1.05--1.51, *P*~heterogeneity~\<0.0001, *I*^2^=83.2%). As for source of controls, high susceptibility to TB was found in PB studies (O vs A: OR =1.18, 95% CI: 1.01--1.38, *P*~heterogeneity~\<0.0001, *I*^2^=72.3%). When stratified by genotyping method, the increased TB susceptibility was shown in polymerase chain reaction--sequence specific primers (PCR-SSP) group among four models: allele model (O vs A: OR =1.27, 95% CI =1.03--1.58, *P*~heterogeneity~\<0.0001, *I*^2^=84.2%), homozygote comparison (OO vs AA: OR =1.96, 95% CI: 1.07--3.57, *P*~heterogeneity~\<0.0001, *I*^2^=76.6%), dominant model (AO/OO vs AA: OR =1.30, 95% CI: 1.01--1.66, *P*~heterogeneity~\<0.0001, *I*^2^=83.0%), and recessive model (OO vs AO/AA: OR =1.75, 95% CI: 1.08--2.84, *P*~heterogeneity~\<0.0001, *I*^2^=63.5%). Further analyses stratified by sample size showed no significant associations between MBL2 exon 1 polymorphisms and TB risk either in "large" or "small" studies. Note that three studies based on Africans are all "large" studies, which may be explained as a negative result in "large" studies.

Heterogeneity and sensitivity analysis
--------------------------------------

Heterogeneity between studies in each model is given in [Table 2](#t2-idr-11-1237){ref-type="table"}. The source of heterogeneity across studies was detected among covariables, including ethnicity, source of controls, sample size, and genotyping method. Meta-regression results revealed that the source of controls (*P*=0.009), but not ethnicity (*P*=0.687), genotyping method (*P*=0.231), and sample size (*P*=0.451) contributed to the source of heterogeneity. When significant heterogeneity existed, we adopted random-effects model; otherwise, we adopted fixed-effects models. To evaluate the effect of individual studies for the risk of overall TB, we performed leave-one-out sensitivity analysis and recomputed the pooled ORs. The estimated pooled ORs calculated after excluding a single study show some differences from the primary values of the overall risk of TB ([Figure 3A](#f3-idr-11-1237){ref-type="fig"}), because the statistical significance is marginal. However, no single study affected the pooled ORs qualitatively in Asians ([Figure 3B](#f3-idr-11-1237){ref-type="fig"}). It suggests that the results of this meta-analysis are stable and robust in Asians.

Publication bias analysis
-------------------------

Begg's funnel plot and Egger's test were conducted to evaluate the publication bias. The shape of the funnel plot both showed symmetry for overall and Asian risk of TB ([Figure 4](#f4-idr-11-1237){ref-type="fig"}). Furthermore, the Egger's test also indicated that there was no evidence for publication bias in all populations (*P*=0.373 for allele model; *P*=0.352 for dominant model) and Asians (*P*=0.632 for allele model; *P*=0.566 for dominant model).

Discussion
==========

TB is an infectious disease caused by *M. tuberculosis*. Although about a third of the world's population are infected with *M. tuberculosis*, only 10% of them develop TB. In addition to factors of environmental, economic, and social status, genetic background of the host may play an important role.[@b44-idr-11-1237] Genetic variations can influence their mechanism of action leading to variable immune response. Host genetic factors such as MBL2 gene polymorphisms can determine differences in the susceptibility or resistance to TB.[@b45-idr-11-1237] Recently, more studies have been conducted to identify whether the polymorphisms of exon 1 of MBL2 is the genetic determiner of TB. However, these studies yielded different or even controversial results. In this meta-analysis, a total of 26 case--control studies, including 7952 cases and 9328 controls, were identified and analyzed. Several similar system reviews had been performed on the association between MBL2 gene polymorphisms and TB risk,[@b12-idr-11-1237],[@b46-idr-11-1237] but it failed to confirm a significant result or in contrast with our study. This meta-analysis first reports that MBL2 exon 1 polymorphisms could predict the susceptibility of TB, especially in Asians.

HWE is essential for a sound case--control study. It is probable that studies without HWE in controls have selection bias or genotyping error, which may cause misleading results. Compared with previous studies, we dropped nine studies[@b47-idr-11-1237]--[@b55-idr-11-1237] with *P*~HWE~\<0.05 to enhance the article rigor and persuasiveness. Frequency distribution of genotypes and alleles of MBL2 exon 1 polymorphisms among different ethnic populations may lead to variable susceptibility to the infection. In this meta-analysis based on 26 eligible studies, we found a marginal significant increased risk in the allele model (O vs A, [Figure 2A](#f2-idr-11-1237){ref-type="fig"}), homozygote comparison (OO vs AA), and dominant model (AO/OO vs AA, [Figure 2B](#f2-idr-11-1237){ref-type="fig"}) in all populations. Although the positive result was first reported, the statistical power was weak while the sensitivity analysis revealed the result was relatively unstable ([Figure 3A](#f3-idr-11-1237){ref-type="fig"}). Moreover, the burden of TB is highest in Asia and Africa geographically. So we performed a subgroup analysis on ethnicity in this meta-analysis ([Figure 2](#f2-idr-11-1237){ref-type="fig"}). It showed that the MBL2 exon 1 polymorphisms had a significantly increased risk of TB only in Asians among all five comparison models. However, no significant association between MBL2 exon 1 polymorphisms and TB risk was found in Caucasians, except a trend of decreased risk was found in Africans. We tried to discuss the further reasons as follows: First, the racial differences of MBL2 exon 1 mutation frequency may be a leading cause. The B allele is common in Caucasians, Chinese, and Eskimos with gene frequencies of 0.11--0.17, while the C allele is almost exclusively present in Africans with a higher frequency (0.23--0.29).[@b10-idr-11-1237],[@b56-idr-11-1237]--[@b58-idr-11-1237] The D allele is present in both Caucasians and Africans with a lower frequency (0.05 in both).[@b3-idr-11-1237] Second, TB types (PTB/EPTB) may influence the pooled result and high variability. For example, the result of Cosar et al study[@b38-idr-11-1237] was quite different from other studies based on Caucasians. In this study, a significant reduction was observed in the frequency of the AO genotype and O allele in TB patients, especially in EPTB patients. Singla et al suggested that the mutant O allele might confer a protective role against TB, but failed in EPTB.[@b27-idr-11-1237] Third, among the nine studies based on Caucasians, Cosar et al[@b38-idr-11-1237] was the only study investigating MBL2 exon 1 polymorphisms in TB-affected children, thus we supposed that age should be also considered as a critical factor accounting for the differences. Fourth, TB susceptibility is usually influenced by codominant multiple genes, and the gene linkage disequilibrium is easy to be ignored.

During other subgroup analyses ([Table 2](#t2-idr-11-1237){ref-type="table"}), we found that different genotyping method might greatly affect the association between MBL2 exon 1 polymorphisms and TB risk. As shown in [Table 2](#t2-idr-11-1237){ref-type="table"}, there was a significantly increased TB risk in studies based on PCR-SSP, but no significant association was found in studies based on polymerase chain reaction-restrictive fragment length polymorphism (PCR-RFLP). Screening for mutations prior to sequencing can reduce the time and costs of identifying mutations. When the DNA sequence is known, the technique of detecting mutations as PCR-SSP and PCR-RFLP are both convenient methods of screening for possible mutations. The differences on subgroup analyses by genotyping method may be due to different primer design and restriction enzyme cutting sites. In addition, the positive results were only found in PTB when stratified by TB types. Compared with PTB, EPTB is difficult to diagnose clinically. Risk factors involved in the development of EPTB are mainly age, female gender, concurrent HIV infection, and comorbidities such as chronic renal disease, diabetes mellitus, or immunosuppression. Less studies on EPTB and its specific pathogenesis may result in above-mentioned differences.

Note that the heterogeneity between studies is quite high in this meta-analysis. The high variability found in available literature may be related to a series of factors such as the ethnic origin of the study population, inadequate selection criteria of controls, small sample size, incomplete genotyping, and so on. In this meta-analysis, we found that only the source of controls might contribute to the high heterogeneity by meta-regression (*P*=0.009). When studies were stratified by ethnicity and source of controls, low heterogeneity was found in Africans and HB studies. Hence, we considered that the racial differences and selection criteria of controls in each study might be responsible for the foremost source of heterogeneity. For example, Asians defined in most studies and this meta-analysis included Indians and Chinese (Han, Uighur, Hui, and Zhuang population) which contribute to obvious racial diversity. In addition, there are great variabilities in the living environment of controls in each study. The gene--environment interaction may influence the results so that it will cause the inevitable heterogeneity.

However, there were some limitations in this meta-analysis. First, we searched English and Chinese databases. Although no publication bias was showed in Begg's funnel plot and Egger's test, it was difficult to avoid the language selection bias completely. Second, the number of studies was relatively insufficient for some subgroup analyses such as by HIV status. It might mask or exaggerate possible true associations. Third, due to lack of detailed individual data, we failed to assess the influence of potential confounding factors more accurately.

Conclusion
==========

In conclusion, we demonstrate that MBL2 exon 1 polymorphisms may contribute to TB risk, especially in Asian populations. Further investigations are needed to confirm the current findings.

Supplementary material
======================

Literature retrieval formula
----------------------------

The exact combination of search terms: (((((((((((polymorphism, single nucleotide) OR SNP) OR polymorphism) OR variant) OR variation) OR allele) OR single nucleotide polymorphism)) AND (('mannose-binding lectin 2') OR MBL2)) AND tuberculosis)) OR (((rs1800450) OR rs1800451) OR rs5030737).
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![PRISMA flowchart. The flow diagram of included and excluded studies.\
**Abbreviations:** MBL2, mannose-binding lectin 2; HWE, Hardy--Weinberg equilibrium.](idr-11-1237Fig1){#f1-idr-11-1237}

![Meta-analysis for the association between the MBL2 exon 1 polymorphisms and tuberculosis risk. Forest plot of (**A**) allele model (O vs A) and (**B**) dominant model (AO/OO vs AA).\
**Note:** The arrow indicates that the lower limit values of the 95% CI are too low to be shown in the figure.\
**Abbreviations:** MBL2, mannose-binding lectin 2; OR, odds ratio.](idr-11-1237Fig2){#f2-idr-11-1237}

![Sensitivity analysis on (**A**) all populations and (**B**) Asians.](idr-11-1237Fig3){#f3-idr-11-1237}

![Funnel plot analysis to detect publication bias. Funnel plot analysis of (**A**) allele model (O vs A) on all populations; (**B**) dominant model (AO/OO vs AA) on all populations; (**C**) allele model (O vs A) on Asians; and (**D**) dominant model (AO/OO vs AA) on Asians.\
**Note:** The circles represent the weight of individual study.\
**Abbreviations:** SE, standard error; OR, odds ratio.](idr-11-1237Fig4){#f4-idr-11-1237}

###### 

Characteristics of eligible studies

  Study                                    Year   Country   Ethnicity   Control   Genotyping method   Type        Cases   Controls   HIV                      
  ---------------------------------------- ------ --------- ----------- --------- ------------------- ----------- ------- ---------- ----- ------ ----- ----- -----
  Bellamy et al[@b40-idr-11-1237]          1998   Gambia    African     HB        PCR-SSP             PTB         198     166        33    183    197   42    --
  Selvaraj et al[@b28-idr-11-1237]         1999   India     Asian       H/N/WB    PCR-SSP             PTB         107     73         22    68     39    2     ND
  Ozbas-Gerceker et al[@b30-idr-11-1237]   2003   Turkey    Caucasian   PB        PCR-SSP             PTB         40      9          0     76     20    4     --
  Soborg et al[@b26-idr-11-1237]           2003   Denmark   Mixed       PB        PCR-SSP             TB          142     60         16    157    86    7     --
  Fitness et al[@b36-idr-11-1237]          2004   Malawi    African     PB        PCR-RFLP            PTB         205     105        12    362    160   24    --
  Garcia-Laorden et al[@b34-idr-11-1237]   2006   Spain     Caucasian   HB        PCR-RFLP            TB          144     79         10    183    134   27    \+
  Selvaraj et al[@b29-idr-11-1237]         2006   India     Asian       HB        PCR-SSP             PTB         24      19         5     37     18    3     --
  Liu et al[@b32-idr-11-1237]              2007   China     Asian       PB        PCR-SSP             PTB         103     34         4     166    42    4     --
  Alagarasu et al[@b43-idr-11-1237]        2007   India     Asian       PB        PCR-SSP             PTB, EPTB   145     87         25    86     53    7     +/−
  Cosar et al[@b38-idr-11-1237]            2008   Turkey    Caucasian   HB        PCR-RFLP            PTB, EPTB   40      4          0     71     27    1     --
  Li[@b19-idr-11-1237]                     2009   China     Asian       PB        PCR-SSP             PTB         79      56         6     106    38    8     --
  Capparelli et al[@b39-idr-11-1237]       2009   Italy     Caucasian   H/N/WB    PCR-RFLP            PTB         55      158        61    166    112   10    --
  Li et al[@b20-idr-11-1237]               2011   China     Asian       PB        Pyrosequencing      PTB         171     57         3     186    37    3     --
  Fang and Yin[@b21-idr-11-1237]           2011   China     Asian       HB        PCR-SSP             PTB         75      25         0     74     25    1     --
  Thye et al[@b25-idr-11-1237]             2011   Ghana     African     H/N/WB    PCR-SSP             PTB         887     814        193   1002   977   257   --
  Singla et al[@b27-idr-11-1237]           2012   India     Asian       PB        PCR-RFLP            PTB, EPTB   218     126        13    207    155   30    --
  Zhou and Zhang[@b22-idr-11-1237]         2012   China     Asian       PB        PCR-SSP             PTB         106     106        14    146    80    5     --
  Ocejo-Vinyals et al[@b31-idr-11-1237]    2012   Spain     Caucasian   PB        PCR-SSP             PTB         74      31         2     272    146   23    --
  Da et al[@b37-idr-11-1237]               2013   Brazil    Caucasian   PB        Sequencing          PTB, EPTB   92      55         8     108    34    6     --
  Araujo et al[@b41-idr-11-1237]           2013   Brazil    Caucasian   HB        PCR-SSP             PTB, EPTB   102     62         3     101    56    2     --
  Garcia-Gasalla et al[@b35-idr-11-1237]   2014   Spain     Caucasian   H/N/WB    PCR-SSP             PTB, EPTB   48      24         4     72     33    1     --
  Zhao et al[@b18-idr-11-1237]             2014   China     Asian       PB        PCR-RFLP            PTB         520     279        101   514    303   53    --
  Wu et al[@b24-idr-11-1237]               2015   China     Asian       HB        PCR-SSP             PTB         112     37         2     348    97    8     --
  Liu et al[@b23-idr-11-1237]              2016   China     Asian       HB        PCR-SSP             PTB         100     36         6     96     22    2     --
  Liu et al[@b33-idr-11-1237]              2016   China     Asian       PB        PCR-RFLP            PTB         645     345        30    748    258   14    --
  Amiri et al[@b42-idr-11-1237]            2017   Iran      Asian       PB        PCR-SSP             PTB         69      29         2     72     27    1     --

**Note:** Mixed=Caucasian/Asian/Africans/Inuits.

**Abbreviations:** PB, population-based; HB, hospital-based; H/N/WB, household/neighboring/working contacts; PCR-SSP, polymerase chain reaction--sequence-specific primers; PCR-RFLP, polymerase chain reaction--restrictive fragment length polymorphism; TB, tuberculosis; PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis; HIV, human immunodeficiency virus; ND, not mentioned.

###### 

Meta-analysis results

  Subgroups                                          N    O vs A                  OO vs AA   AO vs AA                AO/OO vs AA   OO vs AO/AA                                                                           
  -------------------------------------------------- ---- ----------------------- ---------- ----------------------- ------------- ----------------------- ------ ----------------------- ------ ----------------------- ----------
  Total                                              26   **1.18 (1.01--1.38)**   85.8       **1.49 (1.02--2.18)**   79.1          1.17 (0.99--1.37)       78.7   **1.20 (1.01--1.43)**   83.5   1.35 (0.98--1.86)       70.7
  Ethnicity                                                                                                                                                                                                              
  Asian                                              14   **1.29 (1.11--1.51)**   66.0       **1.67 (1.09--2.55)**   54.2          **1.26 (1.05--1.50)**   62.9   **1.31 (1.10--1.56)**   64.2   **1.50 (1.01--2.22)**   48.0
  Caucasian                                          9    1.04 (0.64--1.70)       91.8       1.47 (0.43--4.96)       86.5          1.08 (0.66--1.77)       87.2   1.08 (0.62--1.90)       90.9   1.34 (0.51--3.48)       78.1
  African                                            3    0.93 (0.84--1.02)       15.3       0.83 (0.69--1.00)       0.0           0.94 (0.79--1.12)       43.0   0.92 (0.78--1.09)       42.1   0.86 (0.72--1.03)       0.0
  TB types                                                                                                                                                                                                               
  PTB                                                24   **1.23 (1.04--1.44)**   85.7       **1.58 (1.05--2.36)**   79.2          **1.23 (1.04--1.45)**   77.8   **1.26 (1.05--1.51)**   83.2   1.40 (1.00--1.97)       69.8
  EPTB                                               5    0.86 (0.49--1.50)       65.7       0.65 (0.25--1.64)       0.0           0.87 (0.43--1.79)       68.8   0.97 (0.30--3.06)       89.9   0.51 (0.20--1.27)       0.0
  Source of control                                                                                                                                                                                                      
  PB                                                 14   **1.18 (1.01--1.38)**   72.3       1.36 (0.92--2.03)       59.0          1.18 (0.98--1.43)       71.0   1.20 (1.00--1.44)       71.8   1.26 (0.87--1.84)       54.7
  HB                                                 8    0.98 (0.76--1.25)       63.4       0.79 (0.53--1.18)       5.7           0.96 (0.75--1.24)       50.7   0.96 (0.73--1.27)       60.7   0.83 (0.58--1.19)       0.0
  H/N/WB                                             4    1.64 (0.77--3.49)       96.9       4.88 (0.65--36.84)      95.8          1.51 (0.71--3.25)       94.2   1.74 (0.71--4.27)       96.2   3.48 (0.74--16.30)      93.1
  Genotyping method                                                                                                                                                                                                      
  PCR-SSP                                            17   **1.27 (1.03--1.58)**   84.2       **1.96 (1.07--3.57)**   76.6          1.24 (0.99--1.55)       77.6   **1.30 (1.01--1.66)**   83.0   **1.75 (1.08--2.84)**   63.5
  PCR-RFLP                                           7    0.98 (0.76--1.28)       80.6       0.91 (0.48--1.70)       74.6          0.99 (0.75--1.29)       71.8   0.98 (0.74--1.30)       76.0   0.91 (0.49--1.67)       73.6
  Others                                             2    1.18 (0.69--2.02)       85.0       0.90 (0.63--1.29)       13.9          1.28 (0.65--2.53)       85.4   1.25 (0.64--2.47)       86.6   0.88 (0.73--1.07)       0.0
  Sample size                                                                                                                                                                                                            
  Large[a](#tfn4-idr-11-1237){ref-type="table-fn"}   5    1.08 (0.88--1.33)       88.1       1.19 (0.75--1.89)       83.2          1.04 (0.83--1.31)       83.9   1.07 (0.84--1.35)       86.0   1.20 (0.78--1.85)       \<0.0001
  Small[b](#tfn5-idr-11-1237){ref-type="table-fn"}   21   1.20 (0.96--1.50)       84.8       1.59 (0.88--2.86)       77.1          1.20 (0.96--1.51)       77.2   1.23 (0.96--1.58)       82.9   1.41 (0.87--2.30)       \<0.0001

**Notes:** OR with statistical significance is shown in bold.

studies with \>800 participants;

studies with \<800 participants.

**Abbreviations:** PB, population-based; HB, hospital-based; H/N/WB, household/neighboring/working contacts; TB, tuberculosis; PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis; PCR-SSP, polymerase chain reaction--sequence-specific primers; PCR-RFLP, polymerase chain reaction--restrictive fragment length polymorphism; OR, odds ratio.

[^1]: These authors contributed equally to this work
